Connor, Clark & Lunn Investment Management Ltd. Iveric Bio, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$18.67 - $24.56 $1.31 Million - $1.72 Million	70,123 Added 498.21%	84,198 $2.05 Million
Q4 2022 Feb 10, 2023	SELL	$17.24 - $23.95 $7.11 Million - $9.88 Million	-412,675 Reduced 96.7%	14,075 $301,000
Q3 2022 Nov 10, 2022	BUY	$9.4 - $18.59 $776,853 - $1.54 Million	82,644 Added 24.02%	426,750 $7.66 Million
Q2 2022 Aug 05, 2022	BUY	$9.12 - $18.9 $748,679 - $1.55 Million	82,092 Added 31.33%	344,106 $3.31 Million
Q1 2022 May 12, 2022	BUY	$12.15 - $16.83 $95,802 - $132,704	7,885 Added 3.1%	262,014 $4.41 Million
Q4 2021 Feb 10, 2022	BUY	$13.83 - $18.78 $3.51 Million - $4.77 Million	254,129 New	254,129 $4.25 Million
Q3 2020 Nov 12, 2020	SELL	$4.01 - $6.29 $1.7 Million - $2.67 Million	-424,138 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$3.06 - $6.6 $648,661 - $1.4 Million	-211,981 Reduced 33.32%	424,138 $2.16 Million
Q1 2020 May 13, 2020	SELL	$2.83 - $8.44 $154,730 - $461,457	-54,675 Reduced 7.91%	636,119 $2.19 Million
Q4 2019 Feb 12, 2020	SELL	$0.93 - $8.58 $78,552 - $724,709	-84,465 Reduced 10.9%	690,794 $5.93 Million
Q3 2019 Nov 13, 2019	SELL	$1.09 - $1.29 $101,806 - $120,486	-93,400 Reduced 10.75%	775,259 $868,000
Q2 2019 Aug 07, 2019	BUY	$1.21 - $1.48 $1.05 Million - $1.29 Million	868,659 New	868,659 $1.13 Million

Others Institutions Holding ISEE

# of Institutions

Shares Held

250K

Call Options Held

40K

Put Options Held

View Full List

About IVERIC bio, Inc.

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

More about ISEE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account